Table 3. Treatment outcomes of the included studies.

Study	Postoperative Treatment	Treatment (surgery/local ablation) (n)	Follow-up (mo.)	Recurrence rate (%)			Survival rate (%)
				1-year	2-year	3-year	1-year	2-year	3-year
Yoshiji et al. [9]	VK2 (45 mg)	0/18	48.0	22.2	44	61.1	100	94.4	88.9
	Control arm	0/25	48.0	24.0	48.0	68.0	100	92.0	88.0
	Perindopril+VK2 (45 mg)	0/25	48.0	12.0	28.0	32.0	100	100	96.0
	Perindopril	0/19	48.0	15.8	36.8	52.6	100	94.7	89.5
Mizuta et al. [10]	VK2 (45 mg)	1/31	28.9	12.5	39.0	64.3	100	96.6	87.0
	Control arm	3/26	27.7	55.2	83.2	91.6	96.4	80.9	64.0
Kakizaki et al. [11]	VK2 (45 mg)	4/26	-	7.7	51.4	61.2	100	95.0	77.5
	Control arm	7/23	-	28.3	64.1	90.1	95.8	90.2	66.4
Hotta et al. [12]	VK2 (45 mg)	2/19	19.5	23.8	28.6	-	100	100	-
	Control arm	2/22	16.5	33.3	46.5	73.3	87.5	81.7	81.7
Yoshida et al. [13]	VK2 (45 mg)	9/173	36	31.2	-	-	99.2	-	-
	VK2 (90 mg)	5/180	36	37.7	-	-	98.7	-	-
	Control arm	7/174	36	28.2	-	-	97.2	-	-
Kubota et al. [15]	VK2 (45 mg)	50/0	-	20.6	36.9	43.6	-	-	-
	Control arm	51/0	-	30.0	52.0	76.1	-	-	-
Hosho et al. [16]	VK2 (45 mg)	2/21	23.8	26.1	32.8	78.1	100	93.3	85.6
	Control arm	7/42	26.9	49.0	61.7	67.6	93.3	79.1	56.5

Abbreviation: VK2, vitamin K2 analog.